Aurobindo Pharma Ltd
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)
- Market Cap ₹ 67,940 Cr.
- Current Price ₹ 1,160
- High / Low ₹ 1,593 / 994
- Stock P/E 19.5
- Book Value ₹ 557
- Dividend Yield 0.39 %
- ROCE 14.3 %
- ROE 11.2 %
- Face Value ₹ 1.00
Pros
Cons
- The company has delivered a poor sales growth of 6.55% over past five years.
- Company has a low return on equity of 10.2% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 10.4% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8,089 | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | |
5,951 | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,173 | |
Operating Profit | 2,137 | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,551 |
OPM % | 26% | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% |
18 | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 622 | |
Interest | 310 | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 |
Depreciation | 313 | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 |
Profit before tax | 1,533 | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 |
Tax % | 24% | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | 31% |
1,169 | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | |
EPS in Rs | 20.12 | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 59.49 |
Dividend Payout % | 7% | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 7% |
3 Years: | 11% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 4% |
3 Years: | 8% |
TTM: | 7% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 9% |
3 Years: | 30% |
1 Year: | -8% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 12% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 29 | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 |
Reserves | 3,721 | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 |
3,769 | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | |
1,970 | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,869 | |
Total Liabilities | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,785 |
2,722 | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 16,428 | |
CWIP | 310 | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 3,266 |
Investments | 20 | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 |
6,439 | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,839 | |
Total Assets | 9,490 | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,785 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
646 | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | |
-819 | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,876 | |
118 | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | |
Net Cash Flow | -55 | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,169 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 119 | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 |
Inventory Days | 240 | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 |
Days Payable | 137 | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 |
Cash Conversion Cycle | 222 | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 |
Working Capital Days | 162 | 126 | 141 | 122 | 139 | 148 | 120 | 124 | 120 | 119 | 120 | 123 |
ROCE % | 27% | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% | 14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Jun - Aurobindo Pharma Q4 FY25: Rs 31,724 Cr revenue, Rs 6,605 Cr EBITDA, growth in US, Europe; Pen-G fire impact Rs 4 Cr.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Jun
-
Announcement under Regulation 30 (LODR)-Acquisition
28 May - Aurobindo Pharma's subsidiary incorporated CuraTeQ Biologics B.V. in Netherlands to expand biopharma business.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Submission of newspaper publication of financial results for the fourth quarter and year ended March 31, 2025
-
Update On Safety Incident Of April 27, 2025 At Lyfius Pharma Private Limited (A Wholly Owned Stepdown Subsidiary Of The Company)
26 May - Rs. 40 million loss from safety incident; production paused pending pollution board approval.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Jan 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Mar 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018Transcript PPT
-
Sep 2018Transcript PPT
-
Aug 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Mar 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Aug 2017Transcript PPT
-
Aug 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
Jun 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Mar 2017Transcript PPT
-
Feb 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016Transcript PPT
-
Nov 2016TranscriptNotesPPT
-
Sep 2016TranscriptNotesPPT
-
Sep 2016Transcript PPT
-
Aug 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Jun 2016Transcript PPT
-
Feb 2016Transcript PPT
Leading Pharmaceutical Company
The company is India’s 2nd-largest listed pharma company based on revenue & the largest generics company in the US. It is ranked among the top 10 generic companies in 8 European countries. [1]